Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avadel Pharmaceuticals (AVDL) Cash from Financing Activities: 2015-2022

Historic Cash from Financing Activities for Avadel Pharmaceuticals (AVDL) over the last 7 years, with Dec 2022 value amounting to $6.6 million.

  • Avadel Pharmaceuticals' Cash from Financing Activities was N/A to $6.6 million in Q4 2022 from the same period last year, while for Dec 2022 it was $14.5 million, marking a year-over-year change of. This contributed to the annual value of $16.0 million for FY2024, which is 88.20% down from last year.
  • Avadel Pharmaceuticals' Cash from Financing Activities amounted to $6.6 million in Q4 2022, which was down 38.20% from $10.7 million recorded in Q3 2022.
  • Avadel Pharmaceuticals' 5-year Cash from Financing Activities high stood at $122.9 million for Q1 2018, and its period low was -$9.8 million during Q2 2018.
  • Its 3-year average for Cash from Financing Activities is $19.4 million, with a median of $1.1 million in 2020.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first plummeted by 99.93% in 2019, then skyrocketed by 317,143.24% in 2020.
  • Over the past 5 years, Avadel Pharmaceuticals' Cash from Financing Activities (Quarterly) stood at -$76,000 in 2018, then surged by 46.05% to -$41,000 in 2019, then surged by 546.34% to $183,000 in 2020, then surged by 812.50% to $114,000 in 2021, then soared by 9,299.12% to $6.6 million in 2022.
  • Its Cash from Financing Activities was $6.6 million in Q4 2022, compared to $10.7 million in Q3 2022 and -$4.8 million in Q2 2022.